Hematologic Malignancy
Acute Leukemia
CI-CAN-00000399Explore in graph →
Hematologic1,259 active trials30 approved drugs323 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000399Explore in graph →
Clinical trials
4,655 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (720)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03263572 | Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia | recruiting | Phase 2 | 90 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT04774393 | Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia | recruiting | Phase 1 / Phase 2 | 84 | M.D. Anderson Cancer CenterOTHER | 1 |
| May 20, 2026 |
| clinicaltrials |
| NCT04318678 | CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML) | recruiting | Phase 1 | 108 | St. Jude Children's Research HospitalOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT06777979 | CD19-CD22-Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy for Pediatric Patients With Acute Lymphoblastic Leukemia | recruiting | Phase 1 | 30 | St. Jude Children's Research HospitalOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT07591649 | Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCT | recruiting | Phase 1 / Phase 2 | 18 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT03326921 | HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant | recruiting | Phase 1 | 24 | Fred Hutchinson Cancer CenterOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT07220993 | Novel Unedited Allo Cell Therapy For High Risk T-Cell Malignancies Using CD7-Specific Car T Cells | recruiting | Phase 1 | 27 | Baylor College of MedicineOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT05133882 | A Phase Ⅰb/Ⅱ Clinical Study of Clifutinib Besylate Combined With Chemotherapy in the Treatment of Newly Diagnosed AML | recruiting | Phase 1 / Phase 2 | 133 | Sunshine Lake Pharma Co., Ltd.INDUSTRY | 1 | May 15, 2026 | clinicaltrials |
| NCT06928662 | Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse | recruiting | Phase 1 / Phase 2 | 36 | Fred Hutchinson Cancer CenterOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT06222580 | SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation | recruiting | Phase 1 | 30 | Uma BorateOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT06879340 | Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell Malignancies | recruiting | Phase 1 | 54 | University of Kansas Medical CenterOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT07566377 | Cord Blood Transplantation in Children and Young Adults With Blood Cancer | recruiting | Phase 2 | 71 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT07583888 | VABu Conditioning in Elderly AML HSCT | recruiting | Phase 2 / Phase 3 | 20 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT05794880 | MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing | recruiting | N/A | 40 | Medical College of WisconsinOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT06611839 | Venetoclax in Combination With Ivosidenib and Azacitidine for Newly Diagnosed IDH1-Mutated AML(IDH1-AML-2024) | recruiting | Phase 1 / Phase 2 | 23 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT06635681 | Efficacy of Venetoclax Combined With Intensive Chemotherapy in Different Subgroups of AML(DAV-AML-2024) | recruiting | Phase 2 | 380 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT07454226 | ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL | recruiting | N/A | 92 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT07584889 | Efficacy and Safety of CD19-CAR.p40-T in Patients With Relapsed/Refractory CD19-Positive Hematologic Malignancies(CAR-p40-T) | recruiting | Phase 1 / Phase 2 | 10 | Shenzhen University General HospitalOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT07270978 | Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDS(AML-MDS 001) | recruiting | Phase 1 | 23 | University of VirginiaOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT05907057 | An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy. | recruiting | Phase 3 | 245 | Servier Affaires MédicalesINDUSTRY | 4 | May 8, 2026 | clinicaltrials |
| NCT06481735 | TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL | recruiting | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT06928376 | A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients | recruiting | Phase 2 | 160 | Chinese PLA General HospitalOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT07243483 | Study of the Relationship Between the Pharmacokinetics (PK) and Pharmacodynamics of Venetoclax in Patients With Acute Myeloblastic Leukemia(EUREKA-VEN) | recruiting | N/A | 100 | Centre Leon BerardOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT06874946 | Nanobody-Based Anti-CD5 CAR-T for Relapsed/Refractory T-ALL/NHL(Phase I/II) | recruiting | Phase 1 / Phase 2 | 30 | Peking University People's HospitalOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT07522905 | Virtual Buddy Movement Therapy for Psychomotor and Social Development in Pediatric Oncology Patients in Remission | recruiting | N/A | 24 | Comenius UniversityOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT04771572 | Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. | recruiting | Phase 1 | 100 | Newave Pharmaceutical IncINDUSTRY | 1 | May 5, 2026 | clinicaltrials |
| NCT04888741 | Methods of T Cell Depletion Trial (MoTD)(MoTD) | recruiting | Phase 2 | 400 | University of BirminghamOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT04977180 | Cardioprotection in AML(AML 001) | recruiting | Phase 2 | 70 | University of VirginiaOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT07374029 | Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML | recruiting | Phase 1 | 30 | David AviganOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT07564453 | Full-course Immunotherapy Combined With Chemotherapy in Newly Diagnosed B-cell Acute Lymphoblastic Leukemia(FLOW) | recruiting | Phase 2 | 101 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT07551037 | Efficacy and Safety of Autologous Peptide-induced Active Immunity in AML Maintenance Therapy(AML) | recruiting | Phase 1 | 90 | Fujian Medical University Union HospitalOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07561892 | Study of the Effectiveness and Safety of Daunorubicin /Idarubicin ± Silibinin in Treating Newly Diagnosed AML (Non-M3).(AML) | recruiting | Phase 4 | 100 | Fujian Medical University Union HospitalOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07563179 | Bugitinib Combined With Venetoclax and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia | recruiting | Phase 2 | 10 | Shenzhen University General HospitalOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT04256317 | A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study) | recruiting | Phase 2 / Phase 3 | 316 | Taiho Oncology, Inc.INDUSTRY | 10 | Apr 30, 2026 | clinicaltrials |
| NCT05366569 | Bio-CAR-T BS Study | recruiting | — | 45 | Azienda Socio Sanitaria Territoriale degli Spedali Civili di BresciaOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT07420790 | Design and Validation of a Generative AI and Propensity Score Matching Model for the VEN-DEC Phase II Study in Elderly AML Eligible for Allo-SCT; Evaluation of an Exploratory Approach Respect to a Randomized Phase III Trial(VenDec-AI) | recruiting | — | 1,941 | Azienda Socio Sanitaria Territoriale degli Spedali Civili di BresciaOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT07559695 | A Real-world Study on the Efficacy and Safety of Menin Inhibitors as Maintenance After Allo-HSCT | recruiting | — | 20 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT06195891 | Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome | recruiting | Phase 1 | 33 | City of Hope Medical CenterOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT07048535 | CAR T-cell Long-Term Follow-Up, Quality of Life and Adverse Reactions | recruiting | — | 80 | St. Jude Children's Research HospitalOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT07278882 | Using Mobile Technology-assisted Outpatient Maintenance Therapy Pediatric ALL | recruiting | N/A | 100 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT07499765 | Benefits of Formalized Care Support Program Following Acute Leukemia Diagnosis(ANX-LA) | recruiting | N/A | 110 | Centre Henri BecquerelOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT06129734 | Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant | recruiting | Phase 1 / Phase 2 | 20 | Benjamin TomlinsonOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT06735690 | Allogeneic CMV-Specific CD19-CAR T Cells Plus CMV-MVA Triplex Vaccine After Matched Related Donor Hematopoietic Cell Transplant for the Treatment of Patients With High-Risk Acute Lymphoblastic Leukemia | recruiting | Early Phase 1 | 15 | City of Hope Medical CenterOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT03633955 | Pilot Imaging Study of Leukemia(REALIZE) | recruiting | Phase 1 | 60 | University of OklahomaOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT06074666 | Behavioral Parenting Skills as a Novel Target for Improving Pediatric Medication Adherence: Study 3 | recruiting | N/A | 100 | Roswell Park Cancer InstituteOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT06816134 | Study on the Efficacy and Safety of the TmBU Conditioning Regimen in High-risk or Relapsed/Refractory Acute Leukemia | recruiting | Phase 2 | 48 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT05101551 | Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy(PARPAML) | recruiting | Phase 1 | 34 | Norman J. LacayoOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT06599762 | Evaluation of Tranexamic Acid in Myelodysplastic Syndromes and Acute Myeloid Leukemia(MYELO-CAN:TXA) | recruiting | Phase 2 | 75 | University of ManitobaOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT07320235 | Imetelstat Combinations in Relapsed AML(IMAGINE) | recruiting | Phase 1 | 36 | Douglas TremblayOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT03188874 | Clinical AML Registry and Biomaterial Database of the Study Alliance Leukemia (SAL) | recruiting | — | 15,000 | Technische Universität DresdenOTHER | 1 | Apr 21, 2026 | clinicaltrials |
Data updated 23 days agoSource updated May 20, 2026source: clinicaltrials